PharmaEssentia: 2025 saw record revenue and profit, robust U.S. growth, and major expansion investments
قراءة أقل من دقيقة
Revenue and net income surged in 2025, driven by U.S. medicine sales and improved margins. Major investments in manufacturing and clinical trials support future growth, while unresolved arbitration and customer concentration remain key risks.
Original document: PharmaEssentia Corp. [6446] Interim report — Mar. 27 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr